Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC “capitulate”? 

Brian Ko¹, Balazs Halmos²

¹Department of Medicine, ²Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Correspondence to: Balazs Halmos, MD. Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Email: bahalmos@montefiore.org.


Submitted Nov 30, 2018. Accepted for publication Dec 12, 2018.

doi: 10.21037/tlcr.2018.12.05

View this article at: http://dx.doi.org/10.21037/tlcr.2018.12.05

The mesenchymal-epithelial transition factor (MET)/hepatocyte growth factor (HGF) axis is a key pathway in acquired resistance against epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in EGFR-mutated non-small cell lung cancer (NSCLC). The binding of the cognate HGF ligand to MET induces receptor activation, promoting cell proliferation, cell invasion, and cell survival in multiple preclinical cancer models (1). Evidence of MET dysregulation conferring resistance to EGFR TKI therapy was identified as early as 2007 when Engelman and colleagues demonstrated that focal MET amplification drives ERBB3-dependent activation of PI3K and subsequent resistance to gefitinib. Crucially, MET inhibitor monotherapy was not sufficient to overcome gefitinib resistance; combined treatment with a MET inhibitor and gefitinib was required, suggesting that selective pressure exerted by gefitinib causes cancer cells to adapt so that sustained downstream signaling of either the EGFR pathway or MET pathway is sufficient for survival (2), necessitating the concurrent use of both an EGFR inhibitor and a MET inhibitor. These early observations would herald the paramount importance of carefully selecting EGFR-mutated NSCLC patients with documented acquired resistance to primary EGFR TKI therapy in the clinical development of MET inhibitors, as earlier disappointingly negative clinical studies investigating MET inhibitors largely featured unselected NSCLC patient populations.

Further preclinical studies have demonstrated that MET can engage several other cell surface oncogenic receptor tyrosine kinases including AXL and EPHA1 and can induce EGFR to stabilize potentially oncogenic multiprotein complexes with binding partners including CDCP1 and JAK in multiple carcinoma cell lines. In this context, EGFR downstream signaling becomes independent of its kinase function and competitive ATP binding, conferring resistance to ATP-mimetic EGFR TKI monotherapy (3). MET activity can be dysregulated in a variety of ways such as MET or HGF overexpression, MET gene amplification or high gene copy number (GCN) (4). The frequency of MET dysregulation has ranged from 5–26% of NSCLC with acquired resistance to EGFR inhibitors dependent on methods used and thereby constitutes the second most common validated mechanism of EGFR resistance next to EGFR T790M (2,5-8). Specifically, MET amplification appears to be a more frequent resistance mechanism to the third-generation EGFR TKI osimertinib compared to first-generation EGFR TKIs (9). As such, the increasing use of osimertinib for first-line treatment of patients with metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations may dramatically increase the clinical need for efficacious MET inhibitors. Beyond the combination of first-generation EGFR TKIs with MET inhibitors, which the current study addresses with gefitinib and capmatinib, there are early case reports suggesting that the combination of osimertinib and crizotinib has clinical activity against EGFR-mutated NSCLC with acquired resistance to EGFR TKI therapy (10,11).

Small molecule inhibitors of MET range considerably in structure, mechanism of action and selectivity. Class I inhibitors tend to be more selective for MET and bind to
the activation loop adjacent to the hinge region of MET with a U-shaped conformation (12). Class II inhibitors are usually less selective for MET and when binding to MET span the area from the hinge region to the C-helix (12). Both classes I and II are ATP-competitive, but there are other small molecule MET inhibitors, such as tivantinib, that are ATP non-competitive and have high affinity for unphosphorylated MET, strongly inhibiting MET autophosphorylation and subsequent receptor activation (13). Capmatinib is an orally bioavailable and potent type I MET inhibitor with greater than 10,000-fold selectivity for MET over other tested kinases (14). In 2014, acceptable safety and promising preliminary clinical activity of capmatinib in combination with gefitinib was already reported from a single-arm phase Ib/II study which enrolled adult patients with locally advanced or metastatic EGFR-mutated MET-dysregulated NSCLC with progression after EGFR TKI treatment (15). Recently, eagerly awaited results of the entire study have reported out (16).

Regarding MET biomarker selection for the current study, phase Ib patients were required to have MET amplification defined as a MET GCN greater than or equal to five and/or a MET/centromere ratio greater than or equal to 2.0, or MET overexpression defined as greater than or equal to 50% of tumor cells with moderate or strong staining intensity. After completing the current phase Ib study, the investigators determined the recommended phase II dose of capmatinib to be 400 mg by mouth twice daily to be administered with gefitinib 250 mg by mouth daily. For phase II, patients were initially required to have a MET GCN greater than or equal to 5 by FISH or 50% of tumor cells with MET immunohistochemistry (IHC) 2+/3+; this was subsequently amended to a MET GCN greater than or equal to four or 50% of tumor cells with MET IHC 3+. IHC was used to assess changes in downstream pathway activation, such as phosphorylated (p)-MET, p-ERK, p-AKT, and p-S6, in both pre and post-treatment samples. Although both real-time polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH) can accurately assess copy numbers of MET, real-time PCR cannot distinguish between true MET amplification and polysomy (4). MET IHC tends to incorrectly overestimate MET amplification, while FISH and MET/CEP7 ratio can more accurately determine true genomic amplification (5). Thus, MET gene copy number (GCN) was determined with FISH and when additional tumor tissue was available, next-generation sequencing was performed in order to identify and document specific MET mutations (though specific mutations were not mentioned in the manuscript). Other potential predictive biomarkers include MET/CEP7 ratio, but the investigators found that responses corresponded better with MET GCN in the current study.

The primary end point for the phase II portion was overall response rate (ORR) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, which was 29% (29 of 100 patients) in the phase II study and 27% across both phase Ib and phase II studies. While the overall response rate of 29% in the phase II portion seems lower than anticipated, an exploratory subgroup analysis involving a biomarker enriched group of 36 patients with a MET GCN of six or greater, the response rate was 47% (17 of 36 patients). Progression-free survival (PFS) varied by MET GCN; for MET GCN less than four PFS was 3.9 months, for MET GCN in between four and six PFS was 5.4 months and for MET GCN greater than or equal to six PFS was 5.5 months.

The combination of capmatinib and gefitinib was relatively tolerable with treatment-related grade 3/4 adverse events (AEs) in 46 of 161 (29%) patients and treatment discontinuation in 27 of 161 (17%) patients. No notable drug-drug interactions were observed between capmatinib and gefitinib. While the frequency of grade 3/4 AEs is quite high, this compares favorably to treatment-related adverse events with other selective MET inhibitors in clinical development including tepotinib, viltinib, and glesatinib. For comparison, in the recent GEOMETRY mono-1 trial 84% of patients that received capmatinib had an AE with one-third of patients having grade 3/4 AEs.

The current study suggests that there is a therapeutic ceiling for the combination of capmatinib and gefitinib in EGFR-mutated MET-dysregulated NSCLC. IHC was used to assess changes in downstream markers, including p-MET, p-ERK, p-AKT, and p-S6, and at the doses used, excellent inhibition of the pathway could be demonstrated. Despite that, even in the subgroup of patients with a MET GCN greater than or equal to six with an ORR of 47%, PFS was quite short-lived at only 5.5 months without long-term responders. The lack of durable responses raises concerns about possible tumor heterogeneity leading to differential responses to therapy as well as rapid acquired resistance through unknown mechanisms despite concurrent and potent EGFR and MET blockade.

Another drawback is that while the current study addresses the combination of gefitinib and capmatinib, in current clinical practice osimertinib has supplanted gefitinib for the first-line treatment of patients with metastatic...
NSCLC harboring \textit{EGFR} exon 19 deletions or exon 21 L858R mutations; given the rapidly changing treatment landscape for \textit{EGFR}-mutated NSCLC, choosing the most promising interventional drug combination and the most appropriate control arm is difficult. It is also important to note that the current study involved predominantly (81%) Asian patients with Caucasian patients comprising the remainder (19%); further clinical studies are needed to assess whether the observed response rates are generalizable to non-Asian patient populations.

In addition to the current study, preliminary phase II results of the GEOMETRY mono-1 trial were presented at the European Society for Medical Oncology 2018 Congress (17). This multicenter, open-label, phase II study evaluated the efficacy and safety of single-agent capmatinib 400 mg by mouth twice a day orally in adult patients with \textit{EGFR} and \textit{ALK} negative advanced NSCLC harboring \textit{MET} amplification and/or \textit{MET} mutations, in particular \textit{MET} exon-14 skipping. ORR in treatment-naive patients (n=25) was a quite impressive 72% and ORR in previously treated patients (n=69) was 39%. Interestingly, the duration of response was not evaluable yet by the time of analysis, suggesting that many responses were durable, however; specific PFS data are still pending. There is also preliminary phase Ib/II data with another selective \textit{MET} inhibitor, tepotinib, in combination with gefitinib compared to a control arm of pemetrexed plus cisplatin or carboplatin in patients with \textit{EGFR}-mutated NSCLC with acquired resistance to \textit{EGFR} TKI therapy that was recently reported (18). Unfortunately, enrollment was terminated early due to difficulty accruing patients with \textit{MET}-positive disease, defined as the presence of \textit{MET} amplification by FISH or a \textit{MET} IHC score of either 2+ or 3+. Median PFS was similar for the patients (n=31) assigned to oral tepotinib 500 mg daily plus gefitinib 250 mg per day (dose defined during phase I portion of study) compared to those (n=24) assigned to pemetrexed plus cisplatin or carboplatin with a nonsignificant hazard ratio (HR) of 0.71. Subgroup analysis of patients with a \textit{MET} IHC score of 3+ (n=34) demonstrated that the combination of tepotinib and gefitinib was associated with a median PFS of 8.3 versus 4.4 months for chemotherapy and an HR for progression or death of 0.35, as well as an ORR of 68% versus 33% for chemotherapy; for patients in the \textit{MET}-amplified subgroup (n=19), even more promisingly the combination of tepotinib and gefitinib had a median PFS of 21.2 months compared to 4.2 months with chemotherapy with a HR of 0.17, and an ORR of 67% versus 43% for chemotherapy; however very small numbers in these groups make it impossible to reach definitive conclusions. Results of several other studies ongoing in this area are awaited (Table 1).

Combinatorial approaches with molecularly targeted therapies will continue to refine the pursuit of personalized medicine in appropriate subsets of NSCLC patients.

### Table 1: Selected clinical studies of \textit{MET} inhibitors in NSCLC

<table>
<thead>
<tr>
<th>NCT identifier</th>
<th>Drug treatments</th>
<th>Study phase</th>
<th>MET biomarker selection</th>
<th>Primary outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01911507</td>
<td>Capmatinib plus erlotinib</td>
<td>Ib</td>
<td>MET expression by FISH, IHC score of 2–3+, RT-PCR or \textit{MET} mutations</td>
<td>MTD</td>
</tr>
<tr>
<td>NCT02468661</td>
<td>Capmatinib, capmatinib plus erlotinib, cisplatin/carboplatin plus pemetrexed</td>
<td>Ib</td>
<td>MET GCN ≥6</td>
<td>For phase II, PFS up to 2 years</td>
</tr>
<tr>
<td>NCT01982955</td>
<td>Tepotinib plus gefitinib, cisplatin/carboplatin plus pemetrexed</td>
<td>Ib</td>
<td>MET IHC 2–3+, \textit{MET} gene amplification, increased MET GCN by FISH</td>
<td>For phase II, PFS up to 8 months (18)</td>
</tr>
<tr>
<td>NCT02219711</td>
<td>Sitravatinib</td>
<td>II</td>
<td>MET mutations, \textit{MET} amplification, \textit{MET} gene rearrangements</td>
<td>DLT, AUC, Cmax</td>
</tr>
<tr>
<td>NCT02374357</td>
<td>Volitinib plus gefitinib</td>
<td>Ib</td>
<td>Positive MET test from a central lab</td>
<td>Number of adverse events</td>
</tr>
</tbody>
</table>

\textit{MET}, mesenchymal-epithelial transition factor; NSCLC, non-small cell lung cancer; NCT, National Clinical Trial; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; RT-PCR, reverse-transcriptase polymerase chain reaction; MTD, maximum tolerated dose; GCN, gene copy number; PFS, progression-free survival; DLT, dose-limiting toxicity; AUC, area under the curve; Cmax, peak serum concentration.
While the current study by itself might not yield a practical route to an FDA indication for capmatinib, the promising data presented in the recent GEOMETRY mono-1 study suggest that capmatinib merits further clinical investigation and the current study certainly provides hope for such a combination strategy for well-selected patients, particularly with high MET GCN. Recent clinical data with tepotinib may spur further clinical development as well. More questions remain regarding the clinical efficacy of various selective MET inhibitors and the potential impact of including osimertinib as the EGFR TKI of choice in clinical studies, but more fundamental insights into the complex mechanisms governing acquired resistance involving the MET/HGF axis will likely be needed to dramatically improve clinical impact.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

17. Wolf J, Seto T, Han JY, et al. Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14

© Translational lung cancer research. All rights reserved.


**Cite this article as:** Ko B, Halmos B. Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC “capitulate”? Transl Lung Cancer Res 2018;7(Suppl 4):S321-S325. doi: 10.21037/tlcr.2018.12.05